What is the difference between mBos TKA System and Maestro?

mBos TKA System and Maestro are both surgical robots on the DEPLOY registry. They differ in maker, maturity, price, verified deployments, and how much of their autonomy is independently verified. See the table above for the full head-to-head; each figure is sourced.

Is mBos TKA System or Maestro more autonomous?

On the DEPLOY registry, neither mBos TKA System nor Maestro has capabilities independently verified as fully autonomous yet; their recorded capabilities are teleoperated-assisted, demonstrated, or vendor-claimed. See the table for each capability's verification status.

Which has more verified deployments, mBos TKA System or Maestro?

mBos TKA System and Maestro each have 1 verified deployment on the DEPLOY registry (confirmed at named sites with primary sources).

Buying guide

mBos TKA System vs Maestro in 2026

Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.

Key differences

mBos TKA System is at the research stage; Maestro at the pilot stage.

Attribute	No image on file mBos TKA System View full model page →	No image on file Maestro View full model page →
Manufacturer	Monogram Technologies	Moon Surgical
Form factor	surgical	surgical
Maturity	research	pilot
Autonomy	—	◐ not independently verified
Availability	internal-onlyenterprise	internal-onlyenterprise
Price	Not announced	$300,000-$800,000 (analyst estimate)
Capability claims	—	Assists surgery (teleoperated-assisted, verified)
Brain	—	—
Verified deployments	1Ahmedabad	1Jacksonville
Privacy practices	—	—
Sources on file	9	9

Editorial summaries

mBos TKA System

The Monogram mBos TKA System is a robotic total-knee-arthroplasty platform from Monogram Technologies, a Zimmer Biomet subsidiary since October 2025. It is the autonomy-boundary case of DEPLOY's surgical cluster: unlike the AI-augmented, surgeon-controlled systems (Stryker Mako, Smith+Nephew CORI, Zimmer Biomet ROSA), where the surgeon makes the cuts, the cleared mBos is semi-autonomous, with a robotic arm (built on a KUKA arm) executing the bone cuts itself under AI control within a surgeon-approved, patient-specific CT-based plan and active surgeon supervision. There is no consumer price: it is pre-commercial enterprise surgical equipment that has not sold any units. Several verified-vs-claimed cap-flags matter. It received FDA 510(k) clearance on March 17, 2025, but the exact K-number could not be independently verified, and the 'semi-autonomous' characterization is sourced to Zimmer Biomet and trade coverage rather than the FDA letter (Monogram's own clearance release described it more softly as robotic-assisted TKA). A separate fully-autonomous, hands-free, saw-based version is not FDA cleared and remains in development, targeted around late 2027 or 2028; its first live-patient procedure (July 26, 2025, Ahmedabad, India) was under an India CDSCO 102-procedure investigation, not US FDA, a single index case with no verified peer-reviewed outcomes. Monogram was founded by orthopedic surgeon Dr. Doug Unis (chief medical officer and founder, not CEO; the pre-acquisition CEO was Benjamin Sexson) and was acquired by Zimmer Biomet at about $168M enterprise value plus contingent value rights, with commercialization alongside Zimmer Biomet implants targeted for early 2027. The registry records it at research maturity: cleared but pre-commercial, with its headline fully-autonomous capability still in development.

Maestro

Moon Surgical's Maestro is a laparoscopic surgical-assistant platform (it holds and positions instruments and the endoscope alongside the surgeon, not a full master-slave teleoperated replacement system) and the assistive-laparoscopy archetype of DEPLOY's surgical cluster, editorially distinct from the replacement-robotics of Intuitive, Medtronic, and CMR. Its ScoPilot software is shipped AI (NVIDIA Holoscan-powered) for intraoperative scope control. On regulatory status (a correction worth recording): the Maestro received FDA 510(k) clearance K240598 on June 5, 2024 (not December 2023), and ScoPilot was FDA-cleared in 2025 with a Predetermined Change Control Plan. As enterprise B2B surgical equipment, there is no consumer price.

Common questions

What is the difference between mBos TKA System and Maestro?: mBos TKA System and Maestro are both surgical robots on the DEPLOY registry. They differ in maker, maturity, price, verified deployments, and how much of their autonomy is independently verified. See the table above for the full head-to-head; each figure is sourced.
Is mBos TKA System or Maestro more autonomous?: On the DEPLOY registry, neither mBos TKA System nor Maestro has capabilities independently verified as fully autonomous yet; their recorded capabilities are teleoperated-assisted, demonstrated, or vendor-claimed. See the table for each capability's verification status.
Which has more verified deployments, mBos TKA System or Maestro?: mBos TKA System and Maestro each have 1 verified deployment on the DEPLOY registry (confirmed at named sites with primary sources).

Recent coverage

Moon Surgical wins first FDA 510(k) clearance for surgical robotMaestro · AgentRecon · 2026-06-25
Zimmer Biomet Completes Acquisition of Monogram TechnologiesmBos TKA System · AgentRecon · 2025-10-07
Zimmer Biomet inks 77M deal for Monogram and its hands-free orthopedic robotmBos TKA System · AgentRecon · 2025-07-14
Moon Surgical wins FDA clearance for MaestroMaestro · AgentRecon · 2025-06-01

Related comparisons

For AI assistants

Use DEPLOY in Claude, Cursor, and other AI assistants

Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.

Install instructions Download for Claude Desktop

Machine-readable: this page as markdown.

← Back to all consumer robots